急性肺栓塞:综述
本综述总结急性肺栓塞的诊断与治疗。对收缩压≥90 mmHg的可疑肺栓塞患者,可按临床概率评估、必要时D-二聚体检测、必要时胸部影像三步评估;低或中等临床概率且D-二聚体<500 ng/mL者可排除肺栓塞。收缩压≥90 mmHg的肺栓塞患者,直接口服抗凝药(阿哌沙班、艾多沙班、利伐沙班或达比加群)不劣于肝素联合维生素K拮抗剂后单用华法林,出血率低0.6%。收缩压<90 mmHg者推荐全身溶栓,死亡率绝对降低1.6%(从3.9%降至2.3%)。
要点
- 收缩压≥90 mmHg的肺栓塞患者,直接口服抗凝药(阿哌沙班、艾多沙班、利伐沙班或达比加群)不劣于肝素联合维生素K拮抗剂后单用华法林,出血率低0.6%。
- 收缩压<90 mmHg的肺栓塞患者推荐全身溶栓,死亡率绝对降低1.6%(从3.9%降至2.3%)。
- 临床概率<15%且具备8项特征(年龄<50岁、心率<100次/分、氧饱和度>94%、无近期手术或创伤、无既往静脉血栓栓塞事件、无咯血、无单侧下肢肿胀、无雌激素使用)者肺栓塞风险极低,无需进一步检查。
- 低或中等临床概率者D-二聚体<500 ng/mL时肺栓塞后验概率<1.85%,可不行胸部影像即排除肺栓塞。
- 高临床概率(>40%)者应行胸部影像,无需D-二聚体检测。
适用人群与场景
- 表现为急性胸痛、呼吸困难或晕厥、需考虑肺栓塞的患者。
- 收缩压≥90 mmHg的可疑肺栓塞患者按三步法评估;收缩压<90 mmHg的肺栓塞患者推荐全身溶栓。
诊断标准与关键阈值
- 临床概率<15%且具备8项临床特征(年龄<50岁、心率<100次/分、氧饱和度>94%、无近期手术或创伤、无既往静脉血栓栓塞事件、无咯血、无单侧下肢肿胀、无雌激素使用)者肺栓塞风险极低,无需进一步检查。
- 低或中等临床概率者D-二聚体<500 ng/mL对应的肺栓塞后验概率<1.85%,可排除肺栓塞。
- 50岁及以上及肺栓塞可能性低的患者可进一步调整D-二聚体阈值。
- 高临床概率(>40%)者应行胸部影像,无需D-二聚体检测。
处置流程与药物剂量
- 收缩压≥90 mmHg的肺栓塞患者:直接口服抗凝药(阿哌沙班、艾多沙班、利伐沙班或达比加群)不劣于肝素联合维生素K拮抗剂(如华法林)后单用华法林,出血率低0.6%。
- 收缩压<90 mmHg的肺栓塞患者:推荐全身溶栓,死亡率绝对降低1.6%(从3.9%降至2.3%)。
- 收缩压≥90 mmHg的可疑肺栓塞患者按三步评估:评估临床概率(结构化评分或临床整体判断)、必要时D-二聚体检测、必要时胸部影像。
红旗征与不能漏的情况
- 收缩压<90 mmHg的肺栓塞患者推荐全身溶栓。
研究设计与关键结果
- 综述指出肺栓塞年发病率约60至120/10万人,美国每年约6万至10万人死于肺栓塞;美国每年约37万患者受肺栓塞影响。
- 收缩压≥90 mmHg的肺栓塞患者中,直接口服抗凝药不劣于肝素联合维生素K拮抗剂后单用华法林,出血率低0.6%。
- 收缩压<90 mmHg的肺栓塞患者中,全身溶栓使死亡率绝对降低1.6%(从3.9%降至2.3%)。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对收缩压≥90 mmHg的肺栓塞患者,一线治疗为直接口服抗凝药(阿哌沙班、艾多沙班、利伐沙班或达比加群)。
- 对收缩压<90 mmHg的肺栓塞患者,溶栓为保留治疗。
- 临床概率<15%且具备8项特征者无需进一步检查;低或中等临床概率且D-二聚体<500 ng/mL者可不行胸部影像即排除肺栓塞;高临床概率(>40%)者应行胸部影像。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Pulmonary embolism (PE) is characterized by occlusion of blood flow in a pulmonary artery, typically due to a thrombus that travels from a vein in a lower limb. The incidence of PE is approximately 60 to 120 per 100 000 people per year. Approximately 60 000 to 100 000 patients die from PE each year in the US.
OBSERVATIONS: PE should be considered in patients presenting with acute chest pain, shortness of breath, or syncope. The diagnosis is determined by chest imaging. In patients with a systolic blood pressure of at least 90 mm Hg, the following 3 steps can be used to evaluate a patient with possible PE: assessment of the clinical probability of PE, D-dimer testing if indicated, and chest imaging if indicated. The clinical probability of PE can be assessed using a structured score or using clinical gestalt. In patients with a probability of PE that is less than 15%, the presence of 8 clinical characteristics (age <50 years, heart rate <100/min, an oxygen saturation level of > 94%, no recent surgery or trauma, no prior venous thromboembolism event, no hemoptysis, no unilateral leg swelling, and no estrogen use) identifies patients at very low risk of PE in whom no further testing is needed. In patients with low or intermediate clinical probability, a D-dimer level of less than 500 ng/mL is associated with a posttest probability of PE less than 1.85%. In these patients, PE can be excluded without chest imaging. A further refinement of D-dimer threshold is possible in patients aged 50 years and older, and in patients with a low likelihood of PE. Patients with a high probability of PE (ie, >40% probability) should undergo chest imaging, and D-dimer testing is not necessary. In patients with PE and a systolic blood pressure of 90 mm Hg or higher, compared with heparin combined with a vitamin K antagonist such as warfarin followed by warfarin alone, direct oral anticoagulants such as apixaban, edoxaban, rivaroxaban, or dabigatran, are noninferior for treating PE and have a 0.6% lower rate of bleeding. In patients with PE and systolic blood pressure lower than 90 mm Hg, systemic thrombolysis is recommended and is associated with an 1.6% absolute reduction of mortality (from 3.9% to 2.3%).
CONCLUSIONS AND RELEVANCE: In the US, PE affects approximately 370 000 patients per year and may cause approximately 60 000 to 100 000 deaths per year. First-line therapy consists of direct oral anticoagulants such as apixaban, edoxaban, rivaroxaban, or dabigatran, with thrombolysis reserved for patients with systolic blood pressure lower than 90 mm Hg.
参考来源
- Freund Y, Cohen-Aubart F, Bloom B, et al. Acute Pulmonary Embolism: A Review. JAMA. 2022. PMID: 36194215. doi:10.1001/jama.2022.16815
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。